1130155-48-4

Basic information

• Product Name: (E)-4-(diMethylaMino)but-2-enoic acid (Hydrochloride)
• Synonyms: (2E)-4-(Dimethylamino)-2-butenoic acid hydrochloride (1:?);(E)-4-(DiMethylaMino)but-2-enoic acid xhydrochloride;-4-(Dimethylamino);but-2-enoic acid xhydrochloride
• CAS NO: 1130155-48-4
• Molecular Formula: C6H12ClNO2
• Molecular Weight: 165.61798
• Mol File: 1130155-48-4.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (E)-4-(diMethylaMino)but-2-enoic acid (Hydrochloride)(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-(diMethylaMino)but-2-enoic acid (Hydrochloride)(1130155-48-4)
• EPA Substance Registry System: (E)-4-(diMethylaMino)but-2-enoic acid (Hydrochloride)(1130155-48-4)

Safety Data

• Hazardous Substances Data: 1130155-48-4(Hazardous Substances Data)

Usage

Description

(E)-4-(dimethylamino)but-2-enoic acid (Hydrochloride) is an organic compound with a unique chemical structure featuring a dimethylamino group and a butenoic acid backbone. It is a hydrochloride salt, which contributes to its stability and solubility in water. (E)-4-(diMethylaMino)but-2-enoic acid (Hydrochloride) has gained attention in the field of medicinal chemistry due to its potential applications in the development of pharmaceuticals.

Uses

Used in Pharmaceutical Industry:
(E)-4-(dimethylamino)but-2-enoic acid (Hydrochloride) is used as a key intermediate in the synthesis of tricyclic nitrogen heterocyclic compounds and related heteroanalogs. These complex organic molecules have demonstrated potential in the prevention or treatment of cancer, making this compound a valuable building block in the development of novel anticancer drugs.
In the pharmaceutical industry, the compound serves as a crucial component in the creation of new chemical entities that target specific biological pathways and mechanisms associated with cancer. Its unique structure allows for the formation of diverse tricyclic nitrogen heterocyclic compounds, which can be further optimized for improved efficacy, selectivity, and reduced side effects.
Furthermore, the use of (E)-4-(dimethylamino)but-2-enoic acid (Hydrochloride) in the synthesis of these heterocyclic compounds enables researchers to explore a wide range of structural variations and modifications. This flexibility is essential for the discovery of new drugs with improved pharmacological properties, such as increased potency, better pharmacokinetics, and enhanced safety profiles.
Overall, the application of (E)-4-(dimethylamino)but-2-enoic acid (Hydrochloride) in the pharmaceutical industry highlights its importance in the ongoing quest for innovative and effective cancer therapies. Its role as a versatile intermediate in the synthesis of tricyclic nitrogen heterocyclic compounds and related heteroanalogs positions it as a promising candidate for further research and development in the field of medicinal chemistry.

Upstream product

• 1421354-12-2 (E)-4-dimethylamino-but-2-enoic acid tert-butyl ester 
• 13991-36-1 4-bromocrotonic acid 
• 124-40-3 dimethyl amine 
• 98552-51-3 ethyl 4-(dimethylamino)crotonate 
• 1259519-60-2 4-dimethylaminocrotonic acid methyl ester hydrochloride 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1255078-56-8 (E)-ethyl 4-(dimethylamino)but-2-enoate hydrochloride 
• 212776-19-7 (E)-4-(dimethylamino)-2-butenoic acid methyl ester 
• 1413945-87-5 dimethylaminoacetaldehyde-hydrogen sulphite adduct 
• 88738-78-7 bis-(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate 

Downstream Products

• 1202755-89-2 (E)-4-(dimethylamino)-N-(3-(5-fluoro-4-(m-tolylamino)pyrimidin-2-ylamino)phenyl)but-2-enamide 

Relevant articles and documents

A EGFR molecule targeting anti-tumor pharmaceutical preparation method

The invention relates to a preparation method for an EGFR molecule targeting antitumor drug, and provides a preparation method for (E)-N-[4-(3-acetylene phenyl)amino-3-cyan-7-ethoxy-6-quinolyl]-4-(dimethyl amino)-2-butylene amide. The preparation method comprises the following steps: N-(4-chloro-3-cyan-7-ethoxy quinoline-6-yl) acetamide (a compound II) and 3-aminophenylacetylene (a compound III) are subjected to a substitution reaction, and a compound IV is obtained; under an acidic or alkaline condition, the compound IV is subjected to a hydrolysis reaction, and 3-cyan-6-amino-7-ethoxy-4-(3-acetenyl anilino) quinoline (a compound V) is obtained; after trans-4-dimethylaminocrotonic acid hydrochloride (a compound VI) and an acylation reaction reagent is subjected to an acylation reaction, the product and 3-cyan-6-amino-7-ethoxy-4-(3-acetenyl anilino) quinoline (the compound V) are subjected to condensation reaction, and the finished product is obtained. The method is advantageous in that raw materials are easily available, the technology is concise, the production cost is low, and the method is economical and environmentally friendly and is suitable for industrial production.

Synthetic method for (2Z)-4-(dimethylamino)but-2-enoic acid hydrochloride

The invention discloses a synthetic method for (2Z)-4-(dimethylamino)but-2-enoic acid hydrochloride. The synthetic method comprises the following steps: under an inert gas atmosphere, dissolving [bi(2,2,2-trifluoroethoxy)-phosphinyl]methyl acetate in organic solvent, adding lithium reagent, adding alkali solution, controlling the temperature to 0-30 DEG C, adding 2-(dimethylamino)acetaldehyde sulfite, and carrying out stirring reaction, carrying out acidification, extraction and column purification after reaction to obtain the (2Z)-4-(dimethylamino)but-2-enoic acid hydrochloride. The syntheticmethod has the advantages of convenience in operation and high yield, and industrial production can be realized.

QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed are a quinazoline derivative, a preparation method therefor, and a pharmaceutical composition and an application thereof. The present invention provides a compound represented by general formula I, a stereoisomer thereof and a pharmaceutical acceptable salt or a solvate thereof. The quinazoline derivative of the present invention has a unique chemical structure, is characterized by irreversibly inhibiting EGFR tyrosine kinase, has high biological activity, apparently improves the inhibiting effect on the EGFR tyrosine kinase, has quite strong tumor inhibiting effect on tumor cells and a transplantation tumor pathological model of animal tumors, and has good market developing prospects.